tiprankstipranks
PT Kalbe Farma Tbk (PTKFF)
:PTKFF
US Market

PT Kalbe Farma Tbk (PTKFF) Price & Analysis

Compare
5 Followers

PTKFF Stock Chart & Stats


---

Financials

Quarterly

Options Prices

Currently, No data available
---

Ownership Overview

0.11%99.89%
Insiders
0.11% Other Institutional Investors
99.89% Public Companies and
Individual Investors

PTKFF FAQ

What was PT Kalbe Farma Tbk’s price range in the past 12 months?
PT Kalbe Farma Tbk lowest stock price was $0.06 and its highest was $0.14 in the past 12 months.
    What is PT Kalbe Farma Tbk’s market cap?
    PT Kalbe Farma Tbk’s market cap is $3.05B.
      When is PT Kalbe Farma Tbk’s upcoming earnings report date?
      PT Kalbe Farma Tbk’s upcoming earnings report date is Mar 27, 2025 which is in 23 days.
        How were PT Kalbe Farma Tbk’s earnings last quarter?
        PT Kalbe Farma Tbk released its earnings results on Oct 30, 2024. The company reported $0.001 earnings per share for the quarter, beating the consensus estimate of N/A by $0.001.
          Is PT Kalbe Farma Tbk overvalued?
          According to Wall Street analysts PT Kalbe Farma Tbk’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does PT Kalbe Farma Tbk pay dividends?
            PT Kalbe Farma Tbk pays a Annually dividend of $0.001 which represents an annual dividend yield of 2.52%. See more information on PT Kalbe Farma Tbk dividends here
              What is PT Kalbe Farma Tbk’s EPS estimate?
              PT Kalbe Farma Tbk’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does PT Kalbe Farma Tbk have?
              PT Kalbe Farma Tbk has 46,875,125,000 shares outstanding.
                What happened to PT Kalbe Farma Tbk’s price movement after its last earnings report?
                PT Kalbe Farma Tbk reported an EPS of $0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of PT Kalbe Farma Tbk?
                  Currently, no hedge funds are holding shares in PTKFF
                  ---

                  Company Description

                  PT Kalbe Farma Tbk

                  PT Kalbe Farma Tbk engages in the development, production, distribution, and trade of pharmaceutical products. It operates through the following segments: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution & Logistic. The Prescription Pharmaceutical segment offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores throughout Indonesia. The Consumer Health segment provides over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals segment sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution & Logistic segment maintains distribution of the company's and third party principal's products across Indonesia, and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.
                  ---

                  PTKFF Stock 12 Month Forecast

                  Average Price Target

                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2020","6":"Dec<br/>2020","9":"Mar<br/>2021","12":"Jan<br/>2022","25":"Jan<br/>2023"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.1,0.09230769230769231,0.08461538461538462,0.07692307692307693,0.06923076923076923,0.06153846153846154,0.05384615384615385,0.046153846153846156,0.038461538461538464,0.03076923076923077,0.023076923076923078,0.015384615384615385,0.007692307692307693,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.1,"date":1590969600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1593561600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1596240000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1598918400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1601510400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.09,"date":1604188800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1606780800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1609459200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1612137600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1614556800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1617235200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1617235200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.1,"date":1640995200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Dr Reddy's Laboratories
                  Teva Pharmaceutical
                  GlaxoSmithKline
                  Sanofi
                  Novartis
                  Pfizer

                  Best Analysts Covering PTKFF

                  1 Year
                  No data currently available
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis